A clinical study on Meganathi kuligai for UthiraVatha suronitham(Rheumatoid Arthritis)

A prospective open labelled non randomized phase II clinical study on Mekanati kulikai for uthiravata curonitam (Rheumatoid arthritis)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/03/024153

Enrollment

Registered

2020-03-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified

Interventions

Intervention1: Meganathi Kuligai: 1/2-1 Kundri Edai (60-130mg)/kg BW/Twice a day(orally) with honey for 45 days Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1.Symmetrical joint involvement 2.Involvement of 3 or more joints 3.Florid morning stiffness and swelling that lasts for few hours or days 4.pain,joint swelling especially in the interphalangeal joints 5.pain criteria score should be greater than or equal to 6.

Exclusion criteria

Exclusion criteria: 1.Psoriatic arthritis 2.Gout 3.Mixed connective tissue disorders 4.SLE

Design outcomes

Primary

Measure	Time frame
1.Reducing the pain, swelling, early morning stiffness,deformities. 2.To assess improvement based on the disease activity pain score.Timepoint: 6 weeks	—

Secondary

Measure	Time frame
1.Evaluation of addition effects and siddha parameters during trial period. 2. Determination of safety profile of trial drug . 3. Evaluation of Bio Chemical investigation parameters.Timepoint: 45 days	—

Countries

India

Contacts

Public ContactDr A Manoharan MD s PhD

Government siddha medical college and hospital

drmanoharan25@gmail.com9443886700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026